Ziopharm Oncology (ZIOP +3.3%) perks up on average volume in reaction to its announcement that the FDA has signed off on a National Cancer Institute-sponsored study evaluating T-cell receptor (TCR) T-cell therapy using the company’s Sleeping Beauty platform for the treatment of solid tumors.
Sleeping Beauty is a non-viral gene transfer technology that the NCI will use to generate neoantigen-specific T cells.
The company will host a conference call on Wednesday, June 12, at 8:30 am ET to discuss its non-viral TCR-T program.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.